Allspring Global Investments Holdings LLC Sells 24,164 Shares of Repligen Co. (NASDAQ:RGEN)

Allspring Global Investments Holdings LLC cut its holdings in shares of Repligen Co. (NASDAQ:RGEN - Free Report) by 8.7% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 254,054 shares of the biotechnology company's stock after selling 24,164 shares during the quarter. Allspring Global Investments Holdings LLC owned about 0.45% of Repligen worth $37,808,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the business. CWM LLC increased its holdings in shares of Repligen by 19.9% during the 1st quarter. CWM LLC now owns 361 shares of the biotechnology company's stock worth $66,000 after acquiring an additional 60 shares during the last quarter. Toronto Dominion Bank grew its holdings in Repligen by 1.5% in the 2nd quarter. Toronto Dominion Bank now owns 5,207 shares of the biotechnology company's stock valued at $656,000 after buying an additional 75 shares in the last quarter. DekaBank Deutsche Girozentrale grew its holdings in Repligen by 1.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 7,839 shares of the biotechnology company's stock valued at $982,000 after buying an additional 89 shares in the last quarter. Diversified Trust Co grew its holdings in Repligen by 3.7% in the 2nd quarter. Diversified Trust Co now owns 2,949 shares of the biotechnology company's stock valued at $372,000 after buying an additional 106 shares in the last quarter. Finally, GAMMA Investing LLC grew its holdings in Repligen by 24.0% in the 3rd quarter. GAMMA Investing LLC now owns 594 shares of the biotechnology company's stock valued at $88,000 after buying an additional 115 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have commented on RGEN. Benchmark reaffirmed a "hold" rating on shares of Repligen in a report on Monday, August 5th. UBS Group cut their target price on Repligen from $205.00 to $185.00 and set a "buy" rating for the company in a research report on Wednesday, July 31st. Wells Fargo & Company started coverage on Repligen in a research report on Tuesday, August 27th. They set an "overweight" rating and a $180.00 target price for the company. Stephens reiterated an "overweight" rating and set a $170.00 target price on shares of Repligen in a research report on Tuesday, July 30th. Finally, Deutsche Bank Aktiengesellschaft upgraded Repligen from a "hold" rating to a "buy" rating and cut their target price for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $190.25.

Repligen Price Performance

Shares of RGEN stock traded down $6.66 on Wednesday, hitting $137.48. 519,379 shares of the company's stock were exchanged, compared to its average volume of 667,150. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.65 and a quick ratio of 5.56. Repligen Co. has a 12 month low of $110.45 and a 12 month high of $211.13. The stock has a market cap of $7.70 billion, a P/E ratio of -3,436.14, a price-to-earnings-growth ratio of 4.24 and a beta of 0.95. The company has a 50 day moving average of $144.24 and a 200 day moving average of $147.63.

Repligen (NASDAQ:RGEN - Get Free Report) last announced its quarterly earnings data on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share for the quarter, hitting the consensus estimate of $0.33. Repligen had a positive return on equity of 3.36% and a negative net margin of 0.32%. The business had revenue of $154.07 million during the quarter, compared to the consensus estimate of $154.11 million. During the same period in the prior year, the company earned $0.53 EPS. Repligen's revenue for the quarter was down 3.2% on a year-over-year basis. On average, equities research analysts predict that Repligen Co. will post 1.45 EPS for the current year.

Insiders Place Their Bets

In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, Director Anthony Hunt sold 22,191 shares of the stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now owns 139,840 shares of the company's stock, valued at approximately $20,328,540.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $165.67, for a total value of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares of the company's stock, valued at approximately $3,190,969.87. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 1.20% of the company's stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.